Ken Bowler
Chief Financial Officer
Replay available
Aktis Oncology, Inc. (AKTS) Q1 2024 Earnings Call
Aktis Oncology, Inc. (NASDAQ: AKTS) Q1 2024 earnings conference call, held 2023-11-13. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Jeff Scheele
Founder & Chief Executive Officer
Dave Eichle
Executive Vice President, Business Development
Anthony Stoss
Analyst
Craig Ellis
Analyst, B. Reilly Securities
Suji De Silva
Analyst, RothMKM
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Aktis Oncology, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.407 -- 00:00:04.489 Good day, ladies and gentlemen, and welcome to the Acoustis Technologies Fiscal 2024 00:00:04.489 -- 00:00:09.852 First Quarter Conference Call. As a reminder, this conference call is being recorded. 00:00:09.852 -- 00:00:14.435 At the conclusion of the company presentation, Acoustis Management will take questions. 00:00:14.435 -- 00:00:20.158 To ask a question, please press star 1 on your telephone keypad to be placed into queue. 00:00:20.158 -- 00:00:23.840 A replay of the call will be available on the Investor Relations section of the Acoustis 00:00:23.840 -- 00:00:27.241 website. Thank you. 00:00:28.032 -- 00:00:30.753 Thank you, operator, and good morning to everyone on the call. 00:00:30.753 -- 00:00:35.216 Welcome to ACOUSIS' first quarter fiscal 2024 conference call. 00:00:35.216 -- 00:00:40.458 We're joined today by our founder and CEO, Jeff Scheele, CFO, Ken Bowler, 00:00:40.458 -- 00:00:44.280 and EVP of business development, Dave Eichle. 00:00:44.280 -- 00:00:48.522 Before we begin, please note that today's presentation includes forward-looking statements 00:00:48.522 -- 00:00:53.065 about our business outlook. All statements other than statements of historical facts 00:00:53.065 -- 00:00:58.362 included in this conference call, such as expectations regarding our strategies and operations, 00:00:58.362 -- 00:01:02.545 including the timing and prospects of product development and customer orders and design 00:01:02.545 -- 00:01:06.808 wins, possible collaborative or partnering relationships, 00:01:06.808 -- 00:01:11.612 litigation matters, and expected financial and operating results, or forward-looking 00:01:11.612 -- 00:01:13.333 statements. 00:01:13.333 -- 00:01:17.656 Such forward-looking statements are predictions b...